Histology of subcutaneous nodules in PD patients treated with continuous apomorphine infusion: Case series and review of the literature
Objective: To examine the histology of subcutaneous nodules after continuous subcutaneous apomorphine infusion (CSAI). Background: CSAI has been used successfully in advanced Parkinson's disease (PD).…Effects of deep brain stimulation in the nucleus entopeduncularis on neuronal network activity after apomorphine-induced deficient sensorimotor gating in a rat model
Objective: Deficient sensorimotor gating induced by dopamine receptor agonists is used as an endophenotype for certain neuropsychiatric disorders, such as Tourette´s syndrome (TS), schizophrenia, and…A multi-centre European comparative survey of advanced therapies (infusion and deep brain stimulation) in Parkinson’s disease
Objective: To address comparative demographic and other variables for Parkinson's disease patients at baseline for infusion therapies (subcutaneous apomorphine (Apo), intrajejunal levodopa (IJLI)) and deep…Sensor based gait analysis: Diagnostic application for apomorphine titration
Objective: The goal of the present study was to quantify individual gait changes by eGaIT during the standardized titration test for subcutaneous apomorphine treatment. Background:…Utility of IgGs subtypes in hemolytic anemia prevention and treatment maintenance in patients treated with continous infusion of apomorphine
Objective: The objetive of our study is to assess the utility of the subtypes IgG direct Coombs test (DCT) in maintenance apomorphine treatment without risk…Quantitative assessment of advanced therapies in Parkinson’s disease using the Parkinson kinetigraph (PKG)
Objective: Our aim was to establish whether objective measurements using the Parkinson's Kinetigraph can detect differences between patients undergoing different advanced therapy with either deep…Efficacy of apomorphine subcutaneous injections in patients with levodopa dose failures and morning akinesia
Objective: To assess the effect of subcutaneous injection of apomorphine (APO) in patients with Parkinson's disease (PD)and morning akinesia who experience dose failures after their…Disease severity is not predictive of the dose required for apomorphine sublingual film (APL-130277) to convert a patient with Parkinson’s disease from OFF to fully ON
Objective: Evaluate whether baseline disease severity is predictive of the effective APL-130277 dose to turn a patient with Parkinson's disease (PD) from OFF to fully…Oral apomorphine film (APL-130277) produces no buccal mucosal irritation: Results of a toxicological study
Objective: Determine the tolerance of and potential for cheek pouch buccal mucosa irritation following the administration of apomorphine film (APL-130277). Background: APL-130277 is a sublingual…APL-130277 is a sublingual film being studied in phase 3 trials to rapidly turn patients ON from OFF episodes by delivering apomorphine via the oral mucosa
Objective: Evaluate if any differences exist in the efficacy of APL-130277 doses to turn a patient with Parkinson's disease (PD) from OFF to fully ON…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.